IRTC
iRhythm Technologies, Inc.167.90
-1.10-0.65%
Dec 16, 4:00:01 PM EST
Earnings Call Transcripts
This Quarter (Q1 '26)
No earnings call transcript available yet
Last Quarter (Q4 '25)
FY Q4 '25
CMS tailwind not in guide
Q&A framed CMS chart-scraping scrutiny as a tailwind for Zio's confirmatory diagnoses, with cost-saving data forthcoming but excluded from conservative 2026 guidance of $870M-$880M revenue. Management detailed Zio AT's >50% 2025 growth to continue ahead of company pace, next-gen MCT's locked mobile gateway addressing cybersecurity for H1 2027 launch, and innovative channels at low-single digits amid new partners. Epic integrations set records, eyeing 25% volume boosts not fully baked in. AI concerns dismissed via superior data, FDA hurdles, EHR stickiness. Tailwinds abound. Watch innovative ramp and CMS plays.
Key Stats
Market Cap
5.41BP/E (TTM)
-Basic EPS (TTM)
-1.61Dividend Yield
0%Recent Filings
8-K
8-K
Q4 revenue surges 27%
iRhythm reported Q4 2025 revenue of $208.9M, up 27.1% from 2024, with gross margin at 70.9% and first-ever positive GAAP net income of $5.6M. Full-year revenue hit $747.1M, up 26.2%, slashing net loss to $44.6M while delivering $34.5M free cash flow. Guidance calls for 2026 revenue of $870M-$880M. Cash swelled to $583.8M.
10-K
FY2025 results
iRhythm delivered FY2025 revenue of $747M, up 26% y/y, driven by 26% volume growth with Zio AT accelerating as a revenue mix percentage amid strong enterprise account adoption, though offset by higher contractual allowance reserves from payer claim denials. Gross margin expanded to 71% from 69%, fueled by scale efficiencies despite component cost inflation and tariffs; operating loss narrowed to $(57)M from $(116)M on disciplined expense control. Q4 momentum sustained revenue acceleration while navigating regulatory remediation and litigation costs. Cash grew to $584M with $81M operating cash flow; $661M convertible notes bolster liquidity. No annual guidance disclosed. Medicare reimbursement changes pose quarterly volatility risk.
8-K
26% YTD revenue growth
iRhythm released its Fall 2025 shareholder engagement presentation on November 12, highlighting $538.2 million year-to-date revenue, up 26% from 2024, with 2025 guidance of $735–$740 million and adjusted EBITDA margin of 8.25%–8.75%. Momentum builds from 30%+ U.S. market penetration, international expansion into Europe and Japan, and innovations like 21-day Zio MCT. Free cash flow turns positive in 2025. Yet FDA warning letter lingers.
10-Q
Q3 FY2025 results
iRhythm's Q3 revenue jumped 31% y/y to $192.9M (derived), fueled by Zio AT growth and enterprise accounts, while gross profit climbed 35% to $137.1M for a 71.1% margin. Operating loss narrowed sharply to $8.4M from $50.3M y/y, thanks to lower acquired IPR&D charges; net loss shrank to $5.2M or $(0.16) per share on 32.2M diluted shares (anti-dilutive). Cash fell to $255.6M with $309.6M in marketable securities, supporting $54.7M YTD operating cash flow, against $648.8M long-term convertible notes due 2029 at 1.5%. $2.5M YTD impairment hit internal-use software. Patent suits from Baxter units drag on.
IPO
Website
Employees
Sector
Industry
ADGM
Adagio Medical Holdings, Inc
1.18+0.35
BEAT
Heartbeam, Inc.
3.44+0.81
BTCY
Biotricity Inc.
0.38+0.04
DXCM
DexCom, Inc.
66.37+0.64
IRIX
IRIDEX Corporation
1.00+0.02
IRMD
iRadimed Corporation
96.87-0.15
IRME
IR-Med Inc.
0.02-0.01
RMD
ResMed Inc.
247.34-5.73
RTGN
RETINALGENIX TECHNOLOGIES INC
3.20+0.00
SENS
Senseonics Holdings, Inc.
6.62-0.17